190 related articles for article (PubMed ID: 37605535)
21. Prognostic stratification in patients with pancreatic ductal adenocarcinoma after curative resection based on preoperative pancreatic contrast-enhanced CT findings.
Li D; Wang L; Cai W; Liang M; Ma X; Zhao X
Eur J Radiol; 2022 Jun; 151():110313. PubMed ID: 35447500
[TBL] [Abstract][Full Text] [Related]
22. Clinical Implications of FDG-PET in Pancreatic Ductal Adenocarcinoma Patients Treated with Neoadjuvant Therapy.
Ikenaga N; Nakata K; Hayashi M; Nakamura S; Abe T; Ideno N; Murakami M; Fujimori N; Fujita N; Isoda T; Baba S; Ishigami K; Oda Y; Nakamura M
J Gastrointest Surg; 2023 Feb; 27(2):337-346. PubMed ID: 36652179
[TBL] [Abstract][Full Text] [Related]
23. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
[TBL] [Abstract][Full Text] [Related]
24. Changes in CRP and CA19-9 during Preoperative Oncological Therapy Predict Postoperative Survival in Pancreatic Ductal Adenocarcinoma.
Nurmi AM; Mustonen H; Haglund C; Seppänen H
Oncology; 2021; 99(11):686-698. PubMed ID: 34412062
[TBL] [Abstract][Full Text] [Related]
25. A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma.
Zhu L; Shen S; Wang H; Zhang G; Yin X; Shi X; Gao S; Han J; Ren Y; Wang J; Jiang H; Guo S; Jin G
BMC Cancer; 2023 Aug; 23(1):790. PubMed ID: 37612635
[TBL] [Abstract][Full Text] [Related]
26. Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Treatment Does Not Predict Pathological Response and Survival in Resectable Pancreatic Ductal Adenocarcinoma.
Strong JS; Vos EL; Mcintyre CA; Chou JF; Gonen M; Tang LH; Soares KC; Balachandran VP; Kingham TP; D'Angelica MI; Jarnagin WR; Drebin J; Kunstman JW; Allen PJ; Wei AC
Am Surg; 2022 Jun; 88(6):1153-1158. PubMed ID: 33517697
[TBL] [Abstract][Full Text] [Related]
27. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
[TBL] [Abstract][Full Text] [Related]
28. The involvement of the hepatic artery is a risk factor for unresectability after neoadjuvant treatment in borderline pancreatic adenocarcinoma.
Secanella L; Busquets J; Peláez N; Sorribas M; Laquente B; Ruiz-Osuna S; Fabregat J
Surg Oncol; 2024 Feb; 52():102027. PubMed ID: 38113726
[TBL] [Abstract][Full Text] [Related]
29. Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma.
Newhook TE; Vreeland TJ; Griffin JF; Tidwell RSS; Prakash LR; Koay EJ; Ludmir EB; Smaglo BG; Pant S; Overman M; Wolff RA; Ikoma N; Maxwell J; Kim MP; Lee JE; Katz MHG; Tzeng CD
Ann Surg; 2023 Mar; 277(3):484-490. PubMed ID: 36649067
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant chemotherapy for pancreatic cancer: Quality over quantity.
Thalji SZ; Aldakkak M; Christians KK; Clarke CN; George B; Kamgar M; Erickson BA; Hall WA; Chisholm P; Kulkarni N; Doucette S; Evans DB; Tsai S
J Surg Oncol; 2023 Jul; 128(1):41-50. PubMed ID: 36960919
[TBL] [Abstract][Full Text] [Related]
31. Robotic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: Analysis of surgical outcomes and long-term prognosis in a high-volume center.
Zhang XP; Xu S; Zhao ZM; Liu Q; Zhao GD; Hu MG; Tan XL; Liu R
Hepatobiliary Pancreat Dis Int; 2023 Apr; 22(2):140-146. PubMed ID: 36171169
[TBL] [Abstract][Full Text] [Related]
32. Optimal Management of Resectable Pancreatic Head Cancer in the Elderly Patient: Does Neoadjuvant Therapy Offer a Survival Benefit?
Rieser CJ; Zenati M; Narayanan S; Bahary N; Lee KK; Paniccia A; Bartlett DL; Zureikat AH
Ann Surg Oncol; 2021 Oct; 28(11):6264-6272. PubMed ID: 33748894
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant therapy contributes to nodal downstaging of pancreatic cancer.
Okada K; Uemura K; Kondo N; Sumiyoshi T; Seo S; Otsuka H; Serikawa M; Ishii Y; Tsuboi T; Murakami Y; Takahashi S
Langenbecks Arch Surg; 2022 Mar; 407(2):623-632. PubMed ID: 34609618
[TBL] [Abstract][Full Text] [Related]
34. Critical issues in pathologic evaluation of pancreatic ductal adenocarcinoma resected after neoadjuvant treatment: a narrative review.
Taherian M; Wang H
Chin Clin Oncol; 2022 Jun; 11(3):21. PubMed ID: 35726190
[TBL] [Abstract][Full Text] [Related]
35. Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic performance of NCCN criteria for resection vs CT-determined resectability.
Jang JK; Choi SJ; Byun JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Hwang DW; Kim SC
J Hepatobiliary Pancreat Sci; 2022 Sep; 29(9):1025-1034. PubMed ID: 35658103
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
[TBL] [Abstract][Full Text] [Related]
37. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
38. Tailoring Adjuvant Chemotherapy to Biologic Response Following Neoadjuvant Chemotherapy Impacts Overall Survival in Pancreatic Cancer.
Ghabi EM; Shoucair S; Ding D; Javed AA; Thompson ED; Zheng L; Cameron JL; Wolfgang CL; Shubert CR; Lafaro KJ; Burkhart RA; Burns WR; He J
J Gastrointest Surg; 2023 Apr; 27(4):691-700. PubMed ID: 36280632
[TBL] [Abstract][Full Text] [Related]
39. Smoking impairs the effect of neoadjuvant FOLFIRINOX on postresection survival in pancreatic cancer.
Leonhardt CS; Pils D; Qadan M; Gustorff C; Sahora K; Klaiber U; Warshaw AL; Prager G; Ferrone CR; Lillemoe KD; Schindl M; Strobel O; Castillo CF; Hank T
Eur J Cancer; 2023 Nov; 193():113293. PubMed ID: 37713740
[TBL] [Abstract][Full Text] [Related]
40. The Revised R Status is an Independent Predictor of Postresection Survival in Pancreatic Cancer After Neoadjuvant Treatment.
Leonhardt CS; Pils D; Qadan M; Jomrich G; Assawasirisin C; Klaiber U; Sahora K; Warshaw AL; Ferrone CR; Schindl M; Lillemoe KD; Strobel O; Fernández-Del Castillo C; Hank T
Ann Surg; 2024 Feb; 279(2):314-322. PubMed ID: 37042245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
